Lataa...

Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression

BACKGROUND: A rapid and early monoclonal (M) protein response during initial therapy in patients with multiple myeloma has been identified as a predictor of superior long-term outcome in some, but not all studies. METHODS: To determine if the parameter of M protein reduction was of value in the rela...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Shah, Jatin, Bladé, Joan, Sonneveld, Pieter, Harousseau, Jean-Luc, Lantz, Keith, Londhe, Anil, Lowery, Colin, Orlowski, Robert Z.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2011
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4149315/
https://ncbi.nlm.nih.gov/pubmed/21328327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25937
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!